Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 9/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539354 | 0.88 | PI4KB (0.53) | LCKPI4KBCA1CA2ALDH1A1 | |
| SCHEMBL539642 | 0.87 | LCK (0.52) | LCKPI4KBCA1CA2ALDH1A1 | |
| SCHEMBL7496332 | 0.83 | LCK (0.48) | LCKPI4KBCA1CA2ALDH1A1 | |
| SCHEMBL24434742 | 0.82 | CA1 (0.42) | LCKPI4KBCA1CA2ALDH1A1 | |
| SCHEMBL24434747 | 0.82 | L3MBTL1 (0.47) | LCKPI4KBCA1CA2ALDH1A1 | |
| SCHEMBL13326568 | 0.81 | LCK (0.56) | LCKPI4KBCA1CA2 | |
| SCHEMBL9529240 | 0.81 | CA1 (0.41) | LCKPI4KBCA1CA2ALDH1A1 | |
| SCHEMBL4257610 | 0.81 | CA1 (0.41) | LCKPI4KBCA1CA2ALDH1A1 | |
| SCHEMBL13609513 | 0.80 | TSHR (0.41) | LCKPI4KBCA1CA2ALDH1A1 | |
| SCHEMBL13609514 | 0.79 | LCK (0.40) | LCKPI4KBCA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150956-A1 | MYC INHIBITORS AND USES THEREOF | STEMSYNERGY THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-7973051-B2 | Aminothiazoles as FBPase inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2227468-A1 | AMINOTHIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| WO-2009068467-A1 | AMINOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150956-A1 | MYC INHIBITORS AND USES THEREOF | MYC, AURKA, AURKC | LCK 856/4885PI4KB 148/4885CA1 4533/4885 |
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | FBP1, SLC5A1, DPP4 | LCK 3717/4885PI4KB 2383/4885CA1 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.